Elosulfase alfa is the first disease modifying treatment for mucopolysaccharidosis type 4A, which is recommended for routine use in the NHS following the collection of ‘real-world’ data, that showed it slowed the progression of the disease.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us